Skip to content
Peptide Atlas
All peptides

Epithalon

Tier 3 · Reported use
Also known as Epitalon · Epithalone · AEDG

The strongest evidence present is Tier 1 human observational data (e.g., src-28 on 6-sulfatoxymelatonin excretion and circadian gene normalization; src-38 Russian mortality cohorts; src-39 epithalamin geroprotector trials). However, these human data are limited to small, often decades-old observational cohorts with variable blinding, largely from a single Russian group (Khavinson/St. Petersburg Institute of Bioregulation and Gerontology), with no human RCTs or hard-endpoint trials. The bulk of substantive mechanistic evidence (telomerase/telomere, lifespan, tumor, oocyte, gene expression) is in vitro and animal, and roughly half the ~110 articles are in Russian.

Half-life
~0.5 h
Routes
Subcutaneous injection · Intramuscular injection · Intranasal (parent pineal preparation)
Goals
longevity · cognitive · immune support
Cost / mg
Not recorded

How it works

Epithalon is a small synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) modeled on epithalamin, a natural extract from the pineal gland. Researchers report that it can switch on telomerase — the enzyme that maintains the protective caps (telomeres) on chromosomes — by increasing production of the hTERT component, and that in lab-grown human cells this lengthened telomeres and let cells divide past their usual limit. It is also studied as a regulator of the body clock, appearing to help restore normal nighttime melatonin production and circadian rhythms, and it acts as an antioxidant. At a deeper level it is proposed to enter the cell nucleus and interact directly with DNA and histone proteins to influence which genes are turned on or off.

Overview

Overview

Epithalon (also spelled Epitalon or Epithalone, and known as AEDG) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (alanine-glutamic acid-aspartic acid-glycine). It has a molecular weight of approximately 390.35 g/mol, the molecular formula C14H22N4O9, and CAS number 307297-39-8.

The peptide was synthesized based on the amino acid composition of epithalamin, a crude polypeptide fraction extracted from bovine pineal glands, and is considered the active tetrapeptide isolate from that extract. It was developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, with development beginning in the 1980s. The AEDG sequence was reportedly first detected as a natural component of the pineal gland in 2017, and some sources describe it as a naturally occurring peptide. It has been studied for roughly 25-30+ years using in vitro, in vivo, and in silico methods, generating around 110 published articles on epithalamin and epithalon (at least half of which are in Russian).

Reported Mechanisms and Findings

Telomerase and telomeres

A 2003 paper by Khavinson and colleagues (PMID 12937682) reported that epithalon induced telomerase activity (hTERT expression), restored enzymatic telomerase activity, and elongated telomeres in cultured human somatic cells, including telomerase-negative fetal fibroblasts. Treated fibroblasts reportedly proliferated to passage 44, exceeding the Hayflick limit (~passage 34) seen in controls. Reported figures include a 2.4x increase in telomerase activation and a +33% increase in telomere length. These findings were reportedly replicated in vitro in 2025 (Siddiqui/Al-Dulaimi et al., PMID 40908429), which described dose-dependent telomere extension in normal cells via hTERT/telomerase upregulation; in telomerase-positive cancer lines the effect reportedly proceeded mainly via the Alternative Lengthening of Telomeres (ALT) pathway.

Epigenetic and transcriptional regulation

Short peptides such as AEDG are proposed to penetrate cell and nuclear membranes and interact directly with DNA and histones. In silico work reports preferential binding to linker histones H1.3 and H1.6 and interaction with specific promoter DNA sequences. In human gingival mesenchymal stem cells, AEDG increased neurogenic differentiation markers (Nestin, GAP43, βTubulin III, Doublecortin) 1.6-1.8x, and in cultured cells it decreased the senescence markers p16 and p21 by 1.56-2.44x.

Neuroendocrine / circadian and antioxidant effects

Epithalon is reported to influence melatonin synthesis and restore circadian rhythms. In old rhesus monkeys it caused a threefold increase in nocturnal melatonin peaks and restored circadian melatonin and cortisol rhythms. In a Tier-1 human observational study it increased urinary 6-sulfatoxymelatonin excretion 1.7x and normalized circadian gene expression (Clock, Csnk1e, Cry2) in leukocytes. It is described as a potent antioxidant, comparable to melatonin and roughly 1000-fold more potent than epithalamin, and in aging oocyte cultures it reduced ROS, increased mitochondrial membrane potential and mtDNA copy number, and reduced apoptosis.

Animal longevity and anti-tumor data

Epithalon/epithalamin reportedly increased lifespan in flies, mice, and rats (roughly 10-30% in rodents; +12.3% mean lifespan in CBA mice; 1.8x lower spontaneous tumor incidence in SHR mice). In transgenic HER-2/neu breast cancer mice, dosing (1 mg SC 5x/week) prolonged average and maximum lifespan, increased tumor-free animals 3.7-fold, and reduced lung metastases, probably via suppression of HER-2/neu expression.

Evidence Context and Caveats

The strongest human evidence consists of small observational cohorts, several from Russian clinical groups, reporting restored melatonin rhythms, improved sleep, immune-cell changes, retinal-function improvements, and (in cohorts followed 6-8 years, often combined with thymalin) reduced mortality — findings that have not been independently confirmed. There are no human RCTs or hard-endpoint trials demonstrating that epithalon extends human lifespan. Much of the underlying literature is old, in Russian, and preclinical. Most human and telomerase research originates from a single research group, and Western replication of the telomerase effect at the same magnitude, and of the epigenetic binding data, is limited. Several specific claims (anti-tumor effects in breast/colorectal cancer, gonadotropin effects, orthopaedic-recovery use, diabetic-retinopathy application, histone binding energies, cardiac gene-expression data) rest on single sources.

Regulatory Status

Epithalon is not approved for any indication in the US, has undergone no FDA or EMA regulatory review, was designated FDA Category 2 (October 2023), and is banned from compounding. It is a research compound only.

What the research shows

272 findings extracted from the 30 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 17 human study findings, 30 animal findings, 13 in vitro findings, 14 expert opinion findings and 2 theoretical findings.

  • human studyAEDG peptide increases 6-sulfatoxymelatonin (6-SOMT) excretion in the urine of middle-aged people1

  • human studyRestored nighttime melatonin peak in elderly humans (n=14)4

  • human studyNormalized circadian cortisol pattern in elderly humans4

  • human studyLimited human clinical data from Russian studies suggest effects on melatonin rhythms, retinal function, and cardiovascular mortality in elderly populations5

  • human studyEpithalamin demonstrates geroprotector activity in humans in clinical trials14

  • human studyEpitalon improves the visual functions in patients with pigmental retinal degeneration14

  • human studyNo human studies regarding effects on cognition or neuroprotection; however, some clinical evidence suggests it may decrease human mortality17

  • human studySeveral Russian clinical trials suggest epithalamin may decrease mortality in older adults with cardiovascular disease, but these results have not been independently confirmed17

Show the remaining 68

  • human studyA study was done on elderly patients showing that epithalon administration increased levels of melatonin and achieved restoration of sleep20

  • human studyStudies have reported that epithalon has effects on gonadotropic hormones (FSH, LH, prolactin) to improve sexual and reproductive functions20

  • human studyEpithalon induces telomerase activity and telomere elongation in human somatic cells with a 33% increase in telomere elongation shown in a study20

  • human studyA human trial was done over a 12-year period with patients treated with epithalon and a placebo group20

  • human studyA frequently cited long-term human observation reported reduced mortality over several years of follow-up in older patients given the pineal peptide preparation21

  • human studySeveral Russian studies report restored melatonin rhythms after Epitalon administration in elderly cohorts23

  • human studyRussian clinical observational cohort studies report reduced mortality in elderly patients over 6–8 years of follow-up, particularly when combined with thymalin24

  • human studyA 266-patient mortality dataset shows 1.6 to 4.1× fewer deaths over 6–8 years from one Russian lab24

  • human studyHuman studies report directional improvement on melatonin secretion, immune-cell counts, and sleep quality, but with small sample sizes and variable blinding28

  • animal+12.3% mean lifespan extension in CBA strain mice4

  • animal1.8x lower spontaneous tumor incidence in SHR strain mice4

  • animalEpitalon exerts geroprotective and neuroendocrine effects6

  • animalAEDG peptide increases longevity in animals10

  • animalAEDG peptide decreases experimental cancerogenesis10

  • animalEpithalon causes a threefold increase in nocturnal melatonin peaks in old rhesus monkeys12

  • animalEpithalon prolonged the average lifetime of transgenic FVB/N mice carrying HER-2/neu breast cancer gene by 13.5%13

  • animalEpithalon prolonged the maximum lifetime of transgenic FVB/N mice by 13.9%13

  • animalEpithalon prolonged the average lifetime of animals without neoplasms by 34.2%13

  • animalEpithalon decelerated the development of age-related disturbances in reproductive activity13

  • animalEpithalon suppressed the formation of neoplasms13

  • animalEpithalon decreased the incidence of lung metastases by 1.6 times13

  • animalEpithalon decreased the incidence of multiple tumors by 2 times13

  • animalEpithalon 3.7-fold increased the number of mice without breast tumors13

  • animalEpithalon decreased the number of animals with 6 or more breast tumors by 3 times13

  • animalEpithalon prolonged the lifetime of mice with breast tumors by 1.4 times13

  • animalEpithalamin increases melatonin production by the pineal gland of rats14

  • animalEpithalamin improves immunological parameters in rats and mice14

  • animalEpithalamin produces anticarcinogenic effects in different experimental models14

  • animalEpithalamin restores the reproductive function in old rats14

  • animalEpithalamin increases the lifespan in rats, mice, and fruit flies14

  • animalEpitalon reproduces the effects of Epithalamin including geroprotector activity14

  • animalEpitalon increases the lifespan of mice and fruit flies14

  • animalEpitalon restores the circadian rhythms of melatonin and cortisol production in old rhesus monkeys14

  • animalEpitalon prolongs the functional integrity of the eye retina in Campbell rats with hereditary Retinitis Pigmentosa14

  • animalBoth epithalamin and epithalon may increase lifespan in flies, mice and rats17

  • animalRodent studies have described effects on lifespan and tumor incidence21

  • animalAnimal studies show restored melatonin, cleaner blood markers, and fewer spontaneous tumors in aged mice24

  • animalAnimal studies show meaningful lifespan extension in mice, rats, and Drosophila25

  • animalRodent studies report 10-30% lifespan extension28

  • in vitroIn normal cells, epitalon demonstrated dose-dependent telomere length extension through hTERT and telomerase upregulation7

  • in vitroEpitalon restored impaired wound healing in HG-injured ARPE-19 cells8

  • in vitroEpitalon treatment significantly decreased frequency of spindle defects during aging at 12h and 24h of culture9

  • in vitroEpitalon treatment significantly decreased abnormal distribution of cortical granules during aging at 12h and 24h of culture9

  • in vitroEpitalon decreased apoptosis of oocytes by 24h of aging9

  • in vitroAEDG peptide decreased p16 and p21 mRNA expression by 1.56-2.44 times in comparison with the control group11

  • in vitroKED peptide decreased p16 and p21 mRNA expression by 1.82-3.23 times in comparison with the control group11

  • in vitroLaboratory work reports telomerase induction and telomere lengthening in human cell lines21

  • in vitroTelomerase activation, measured via hTERT mRNA expression, peaks 24–36 hours post-injection according to in vitro studies on human fibroblasts22

  • in vitroA 2003 paper showed Epithalon switches telomerase — the cell's own anti-aging enzyme — back on in cultured human cells24

  • in vitroThe telomere claim was independently replicated in 202524

  • in vitroEpithalon reactivates telomerase (hTERT) in senescent human fetal fibroblasts and extends replicative lifespan past the Hayflick limit25

  • in vitroOriginal 2003 in-vitro work reported that Epithalon induced measurable telomerase activity in cultured human somatic cells (fibroblasts)28

  • expert opinionNo independent replication of human clinical findings has been published5

  • expert opinionEpithalon extends cellular replicative capacity beyond normal limits by addressing fundamental aging mechanisms at the chromosomal level19

  • expert opinionEpithalon has been shown to have distinctive anti-aging and anti-tumor activity across many animal and human studies20

  • expert opinionEpithalon has been reported to show significant anti-tumor effects in breast and colorectal cancer by inhibiting carcinogenic receptor expression and attenuation of metastasis20

  • expert opinionEpithalon increases endogenous levels of hormones that are lost due to aging20

  • expert opinionNighttime melatonin levels remain elevated for several days after a single dose, despite the peptide clearing within 48 hours22

  • expert opinionThe telomerase reactivation finding has not been independently replicated in Western labs at the same magnitude23

  • expert opinionThe epigenetic binding-affinity data has not been broadly replicated23

  • expert opinionThe telomerase data is primarily from one research group over four decades25

  • expert opinionThere is no human trial showing Epithalon extends human life25

  • expert opinionPreclinical studies on therapeutic peptides including epithalon are promising, but there is a current lack of clinical trials27

  • expert opinionEpithalon has been subject to thirty-year research programme spanning in-vitro telomerase induction, rodent lifespan extension, and small human trials in elderly Russian and Ukrainian cohorts28

  • expert opinionReplication outside the original research consortium has been limited28

  • expert opinionNo hard-endpoint Phase 2/3 trials have been published28

  • theoreticalNon-approved peptides showed promising preclinical findings2

  • theoreticalEpitalon has been extensively studied using in vitro, in vivo, and in silico methods over the last 25 years3

How it works

Based on 4 human study findings, 28 animal findings, 42 in vitro findings, 22 expert opinion findings and 29 theoretical findings.

  • human studyAEDG peptide normalized circadian Clock and Csnk1e genes hyper expression in leukocytes in middle-aged people with reduced melatonin-producing epiphysis function1

  • human studyAEDG peptide increases Cry2 gene hypo expression in peripheral blood lymphocytes in people with reduced melatonin-producing epiphysis function1

  • human studyAEDG peptide restores epiphysis melatonin-producing function by regulation of human circadian genes expression1

  • human studyEpithalamin stimulates melatonin production in elderly adults with pineal gland dysfunction and in old rats17

  • animalEpitalon has antioxidant effects3

  • animalEpitalon has neuroprotective effects3

  • animalEpitalon has antimutagenic effects3

  • animalEpitalon exerts direct influence on melatonin synthesis3

Show the remaining 117

  • animalEpitalon modulates the mitogenic activity of murine thymocytes3

  • animalEpitalon enhances the activity of AChE (acetylcholinesterase)3

  • animalEpitalon enhances the activity of BuChE (butyrylcholinesterase)3

  • animalEpitalon enhances the activity of telomerase3

  • animalEpitalon demonstrates antioxidant, neuro-protective, and antimutagenic effects6

  • animalEpitalon exerts a direct influence on melatonin synthesis6

  • animalEpitalon alters the mRNA levels of interleukin-26

  • animalEpitalon modulates the mitogenic activity of murine thymocytes6

  • animalEpitalon enhances the activity of various enzymes, including AChE, BuChE, and telomerase6

  • animalAEDG peptide (Ala-Glu-Asp-Gly, Epitalon) regulates the function of the pineal gland, the retina, and the brain10

  • animalThe geroprotective effect of AEDG and KED peptide was shown early in animal and cells models11

  • animalEpithalon possesses geroprotective activity13

  • animalEpithalon inhibits breast carcinogenesis in transgenic mice, probably related to suppression of HER-2/neu expression13

  • animalEpithalamin stimulates antioxidant defenses14

  • animalShort peptide preparations produce changes in gene expression14

  • animalEpithalon modulated expression of 98 clones out of 15,247 clones from a cDNA library in the heart of mice15

  • animalEpithalon alone or in combination with Vilon activated expression of 194 clones (maximally by 6.61 times)15

  • animalEpithalon alone or in combination with Vilon inhibited expression of 48 clones (maximally by 2.71 times)15

  • animalEpithalon has specific effects on gene expression in mouse heart15

  • animalPreclinical studies suggest epithalamin may have anti-oxidant activity in the brain and increase melatonin levels17

  • animalEpithalon failed to stimulate melatonin production in rats but was reported to increase melatonin levels in older primates17

  • animalLower levels of DNA damage were observed in senescence-accelerated mice (SAMP-1) treated with epithalon, an effect not observed with melatonin treatment17

  • animalEpithalon may cross the blood-brain barrier, where it may stimulate cortical neurons and increase levels of phosphor-CREB, a DNA-binding protein important in learning and memory17

  • animalBoth epithalamin and epithalon show antioxidant activity and may improve organismal antioxidant defense systems in flies and rats17

  • in vitroEpithalon peptide induces telomerase activity in human somatic cells2

  • in vitroEpithalon peptide induces telomere elongation in human somatic cells2

  • in vitroEpitalon is a tetrapeptide with amino acid composition Ala-Glu-Asp-Gly (AEDG)3

  • in vitroEpitalon was synthesized based on the amino acids composition of Epithalamin, a bovine pineal gland extract3

  • in vitroEpitalon alters the mRNA levels of interleukin-23

  • in vitro2.4x increase in telomerase activation reported in vitro in human fetal fibroblasts4

  • in vitro+33% telomere length increase in human fibroblasts in vitro4

  • in vitroEpithalon has demonstrated superior antioxidant potency at concentrations approximately 1,000-fold lower than epithalamin5

  • in vitroAddition of epithalon to cultures of telomerase-negative human fetal fibroblasts reactivated hTERT expression, restored enzymatic telomerase activity, and produced measurable telomere elongation5

  • in vitroEpithalon-treated fibroblasts continued proliferating to passage 44, exceeding the Hayflick limit observed in control cultures at passage 345

  • in vitroA 2025 study by Siddiqui et al. demonstrated dose-dependent telomere length extension in normal epithelial and fibroblast cells through hTERT upregulation5

  • in vitroIn telomerase-positive cancer cell lines, epithalon-mediated telomere extension occurred primarily through activation of the Alternative Lengthening of Telomeres (ALT) pathway rather than telomerase upregulation5

  • in vitroEpitalon is known for its anti-aging effects on mammalian cells7

  • in vitroAnti-aging effects occur through the induction of telomerase enzyme activity7

  • in vitroInduction of telomerase leads to extension of telomere length7

  • in vitroIn cancer cells, significant telomere length extension occurred through ALT (Alternative Lengthening of Telomeres) activation7

  • in vitroOnly a minor increase in ALT activity was observed in normal cells7

  • in vitroAEDG (Ala-Glu-Asp-Gly, Epitalon) is a synthetic tetrapeptide8

  • in vitroShort peptides have antioxidant, antimicrobial, and anti-inflammatory effects8

  • in vitroHigh glucose (HG) exposure delayed wound healing in ARPE-19 cells8

  • in vitroHigh glucose exposure increased intracellular levels of reactive oxygen species (ROS)8

  • in vitroHigh glucose exposure decreased antioxidant gene expression8

  • in vitroHigh glucose induced epithelial-mesenchymal transition (EMT)8

  • in vitroHigh glucose upregulated fibrosis-related genes8

  • in vitroHG-induced EMT contributes to subretinal fibrosis in diabetic retinopathy8

  • in vitroEpitalon inhibited hyperglycemia-induced EMT and fibrosis8

  • in vitro0.1mM Epitalon reduced intracellular reactive oxygen species in oocyte culture9

  • in vitroEpitalon increased mitochondrial membrane potential in aging oocytes9

  • in vitroEpitalon increased DNA copy number of mitochondria in aging oocytes9

  • in vitroAEDG peptide induces neuronal cell differentiation in retinal and human periodontal ligament stem cells10

  • in vitroAEDG peptide increased the synthesis of neurogenic differentiation markers: Nestin, GAP43, β Tubulin III, Doublecortin in hGMSCs10

  • in vitroAEDG peptide increased Nestin, GAP43, β Tubulin III and Doublecortin mRNA expression by 1.6-1.8 times in hGMSCs10

  • in vitroAEDG peptide preferably binds with H1/6 and H1/3 histones at His-Pro-Ser-Tyr-Met-Ala-His-Pro-Ala-Arg-Lys and Tyr-Arg-Lys-Thr-Gln sites which interact with DNA10

  • in vitroAEDG peptide can epigenetically regulate neuronal differentiation gene expression and protein synthesis in human stem cells10

  • in vitroEpithalamin augments the in vitro outgrowth of explants from the pineal gland but not from other tissues14

  • in vitroIn cell-culture work, Epithalon has been reported to induce telomerase expression and lengthen telomeres in human somatic cells21

  • in vitroKhavinson and colleagues reported in 2003 that AEDG induced telomerase activity and elongated telomeres in cultured human somatic cells, including fetal fibroblasts23

  • in vitroThe 2003 Khavinson paper (PMID 12937682) reported that Epithalon activated telomerase and elongated telomeres in cultured human somatic cells24

  • in vitroEpithalon activates telomerase (hTERT expression) in cultured human somatic cells24

  • in vitroAl-Dulaimi et al. 2025 (PMID 40908429) showed Epithalon increases telomere length in human cell lines through both telomerase upregulation and ALT activity24

  • in vitroDirect induction of telomerase activity in adult somatic cells via TERT-gene expression modulation28

  • in vitroTelomere elongation could be detected in treated cells over multiple passage cycles28

  • expert opinionEpithalon was designed based on amino acid analysis of the epithalamin extract and was intended to reproduce the geroprotective properties of the crude pineal preparation in a defined, synthetic form5

  • expert opinionEpithalon is a four-amino-acid peptide that activates telomerase enzyme to help protect and lengthen telomeres on chromosomes19

  • expert opinionEpithalon directly activates telomerase enzyme to maintain and lengthen chromosome-protecting telomeres19

  • expert opinionEpithalon restores natural melatonin production through pineal gland support, improving sleep onset, quality, and circadian rhythm regulation19

  • expert opinionEpithalon is a short, 4 amino acid chain peptide (Alanine-Glutamate-Asparagine-Glycine) used to regulate the cell cycle through upregulation of telomerase activity20

  • expert opinionEpithalon is known as the synthetic version of the tetrapeptide epithalamin, which naturally occurs in the pineal gland20

  • expert opinionEpithalon regulates the cell cycle through up-regulation of telomerase activity20

  • expert opinionEpithalon has been shown to affect the aging process by exerting an antioxidant effect20

  • expert opinionEpithalon plays a key role in the regulation of important biomolecules such as cytokines, C-reactive protein, and other acute phase reactants to attenuate the inflammatory response20

  • expert opinionEpithalon's 30-minute plasma half-life reflects enzymatic cleavage by peptidases in the bloodstream and liver, followed by renal excretion of amino acid fragments22

  • expert opinionEpithalon binds to receptors in the pineal gland and activates telomerase enzyme expression in cells22

  • expert opinionEpithalon upregulates melatonin synthesis in the pineal gland by influencing circadian expression of enzymes like AANAT22

  • expert opinionEpitalon is a synthetic tetrapeptide composed of four amino acids in sequence: alanine, glutamic acid, aspartic acid, and glycine23

  • expert opinionThe parent compound, epithalamin, was a polypeptide preparation derived from bovine pineal gland23

  • expert opinionShort peptides like AEDG may bind to specific DNA sequences and modulate gene expression directly, acting as transcriptional regulators23

  • expert opinionEpithalon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly derived from bovine pineal gland extract24

  • expert opinionEpithalon is a synthetic four-amino-acid peptide — Ala-Glu-Asp-Gly25

  • expert opinionEpithalon identified by Vladimir Khavinson's group as the active component of Epithalamin, a bovine pineal gland extract25

  • expert opinionPeptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.26

  • expert opinionEpithalon is a recovery-enhancing agent that targets circadian and mitochondrial regulators27

  • expert opinionEpithalon was designed as a synthetic analog of an endogenous pineal-gland peptide complex hypothesised to regulate circadian and neuroendocrine ageing28

  • expert opinionTelomerase induction in adult somatic cells is exceptionally rare outside of stem-cell and germline contexts28

  • theoreticalEpithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly)4

  • theoreticalEpithalon is based on the pineal gland peptide epithalamin4

  • theoreticalPrimary gland target is pineal (melatonin)4

  • theoreticalEpithalon operates through telomerase activation via hTERT upregulation, pineal melatonin restoration, and epigenetic modulation5

  • theoreticalEpithalon binds preferentially to the linker histone proteins H1.3 and H1.6, with calculated binding energies of -56.49 and -64.51 kcal/mol respectively5

  • theoreticalEpithalon interacts with specific DNA sequences (ATTTG and ATTTC), which are present in the promoter region of the telomerase gene5

  • theoreticalEpithalon binds methylated cytosine residues in DNA, suggesting a role in epigenetic regulation5

  • theoreticalEpitalon is a tetrapeptide with amino acid sequence Ala-Glu-Asp-Gly (AEDG)6

  • theoreticalEpitalon was synthesized based on the amino acids composition of Epithalamin, a bovine pineal gland extract6

  • theoreticalEpitalon is a synthetic short peptide made of four amino acids (alanine, glutamic acid, aspartic acid, and glycine)9

  • theoreticalEpitalon is based on a natural peptide called epithalamion extracted from the pineal gland9

  • theoreticalEpitalon is a potent antioxidant, comparable to melatonin9

  • theoreticalAEDG peptide and histones H1/3, H1/6 binding may provide an increase of neuronal differentiation gene transcription10

  • theoreticalShort peptides had geroprotective properties and stimulated stem cell differentiation11

  • theoreticalAge-related changes in the pineal gland are functional rather than organic12

  • theoreticalDietary restriction ameliorates or inhibits some age-related impairments of the pineal gland12

  • theoreticalS-adenosylmethionine ameliorates or inhibits some age-related impairments of the pineal gland12

  • theoreticalMAO-A inhibitors ameliorate or inhibit some age-related impairments of the pineal gland12

  • theoreticalEpithalon effects markedly overlap with melatonin effects12

  • theoreticalEpithalon targets may include transcription factors specific for pineal gland and retina that exhibit impaired functions in aged pineal gland12

  • theoreticalEpitalon (Ala-Glu-Asp-Gly) is a tetrapeptide specific for pineal gland and eye retina14

  • theoreticalEpithalon is a synthetic tetrapeptide with the sequence Alanine-Glutamate-Aspartate-Glycine21

  • theoreticalEpithalon is theorized to help normalize melatonin secretion and circadian rhythm, along with effects on antioxidant and neuroendocrine signaling21

  • theoreticalEpithalon is a tetrapeptide (Ala-Glu-Asp-Gly)22

  • theoreticalShort peptides binding specific DNA sequences to regulate gene expression25

  • theoreticalShort peptides are molecules with small molecular weight, capable of penetrating the cell membrane and nuclear membrane for epigenetic regulation of gene expression29

  • theoreticalShort peptides can take part in activation of the signaling pathways regulating expression of differentiation genes29

  • theoreticalShort peptides can interact with histones changing the availability of genes for transcription, regulate gene methylation and activate or inhibit their expression29

  • theoreticalShort peptides can directly interact with the DNA29

Dosing

Based on 8 expert opinion findings and 6 anecdotal findings.

  • expert opinionStandard dose of Epithalon is 5-10 mg once daily for 10-20 day course, repeated 1-3 times per year via subcutaneous injection19

  • expert opinionGeneral Dosing (Russian Protocol): 100 mg total, 10 mg IM daily for 10 days, twice a year20

  • expert opinionGeneral Dosing (Ukraine Protocol): 50 mg total, 10 mg every third day times 2 weeks, twice a year20

  • expert opinionEpithalon is most often given as a short course of subcutaneous injections, sometimes repeated once or twice a year, with the dose expressed in milligrams per course21

  • expert opinionSome studies used intranasal or intramuscular routes of the parent pineal preparation21

  • expert opinionTypical dosing protocols involve 5–10 days consecutively, repeated monthly or quarterly22

  • expert opinionSignificant knowledge gaps include optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy for peptide therapeutics including epitalon.26

  • expert opinionStandard research route is subcutaneous28

Show the remaining 6

  • anecdotalThe most common protocol is 0.5–1.0 mg daily via subcutaneous injection for 10–20 days, repeated twice per year with a minimum 4-month pause16

  • anecdotalCommunity use is primarily in longevity protocols of 10–20 day courses repeated 1–2× per year24

  • anecdotalStandard cycle: 5 mg (5,000 mcg) sub-Q daily for 20 consecutive days25

  • anecdotalAlternate dosing: 10 mg daily for 10 days25

  • anecdotalOff period: 4–6 months between cycles25

  • anecdotalAnnual frequency: 1–2 cycles per year25

How the body handles it

Based on 10 expert opinion findings, 1 anecdotal finding and 1 theoretical finding.

  • expert opinionEpithalon has high bioavailability when injected subcutaneously19

  • expert opinionEpithalon has a plasma half-life of approximately 30 minutes following subcutaneous injection22

  • expert opinionConcentration in bloodstream drops by half every 30 minutes until the peptide is effectively cleared within 24 to 48 hours22

  • expert opinionWithin 90 minutes of injection, approximately 87.5% of the original dose has been degraded22

  • expert opinionBy the 4-hour mark, plasma levels are below the threshold of standard detection methods22

  • expert opinionEpithalon doesn't accumulate in tissues the way lipophilic compounds do22

  • expert opinionEpitalon is rapidly cleared from circulation, which is part of why injection cycling is the standard delivery model rather than continuous dosing23

  • expert opinionHalf-life approximately 30 minutes in plasma with functional effects lasting weeks to months24

Show the remaining 4

  • expert opinionHalf-life is tiny. Epithalon is chewed up by aminopeptidases in minutes25

  • expert opinionPharmacokinetics in humans are sparse; the peptide is orally inactive28

  • anecdotalReconstitute a 10 mg vial with 2 mL BAC → 5 mg/mL25

  • theoreticalEpithalon is a synthetic peptide Ala-Glu-Asp-Gly designed based on amino acid content of pineal peptide extract Epithalamin12

Safety and side effects

Based on 2 human study findings, 1 animal finding, 7 expert opinion findings, 4 anecdotal findings and 1 theoretical finding.

  • human studyLimited evidence suggests epithalamin is likely safe for long term use17

  • human studyTwo 3-year epithalamin treatment trials (one with a 12-year follow-up) reported no severe adverse events in older adults and preclinical studies support a favorable safety profile17

  • animalKhavinson's tumor data shows lower spontaneous tumor incidence in his mouse cohorts25

  • expert opinionNo FDA or EMA regulatory review for any indication4

  • expert opinionEpithalon is designated Category 2 by FDA (Oct 2023) and banned from compounding5

  • expert opinionepithalon is well tolerated with a favorable safety profile18

  • expert opinioncauses no severe adverse effects in test18

  • expert opinionIn the reported studies and in clinical use, Epithalon has generally been described as well tolerated, with no consistent pattern of serious toxicity at the doses used21

Show the remaining 7

  • expert opinionReported effects are typically mild and self-limiting21

  • expert opinionNon-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation.26

  • anecdotalDrowsiness some users report after injection is consistent with pineal axis activation23

  • anecdotalVivid dreams — very common, almost universal25

  • anecdotalMild drowsiness the next day at higher doses25

  • anecdotalInjection site tenderness — minor, brief25

  • theoreticalTheoretical oncological concern raised by inducing telomerase activity in adult somatic cells has not been adequately addressed28

What people use it for

Based on 4 animal findings, 2 in vitro findings, 6 expert opinion findings, 1 anecdotal finding and 3 theoretical findings.

  • animalEpitalon exerts geroprotective and neuroendocrine effects3

  • animalEpithalon produces life extension in mice12

  • animalEpithalon produces life extension in fruit flies12

  • animalEpithalon postpones vision loss in Campbell rats with hereditary pigmental dystrophy12

  • in vitroEpitalon can delay the aging process of oocytes via modulating mitochondrial activity and ROS levels9

  • in vitroAEDG and KED peptides could be used as supplementary substances in a culture medium to delay the expression of senescence markers in long term stem cell cultivation11

  • expert opinionAEDG peptide is a geroprotector1

  • expert opinionA strong link exists between telomere length and aging-related diseases7

Show the remaining 8

  • expert opinionTelomeres are considered to be one of the biomarkers of aging7

  • expert opinionEpitalon is identified as a peptide with applications in telomere biology26

  • expert opinionEpithalon is used in the management of orthopaedic injuries27

  • expert opinionEpithalon is unscheduled by the FDA and not approved for any indication in the US28

  • anecdotalDeep sleep the first few nights — the signature effect25

  • theoreticalIncreasing or maintaining telomere length may contribute to healthy aging and longevity7

  • theoreticalEpitalon could be used as a therapeutic strategy for diabetic retinopathy8

  • theoreticalEpitalon may confer longevity benefits9

Other findings

Based on 11 expert opinion findings and 3 theoretical findings.

  • expert opinionNo large-scale randomized controlled trials in humans exist4

  • expert opinionTelomere effects not confirmed in human clinical settings4

  • expert opinionMost published research from a single laboratory group4

  • expert opinionEpithalon was developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of epithalamin, a polypeptide fraction extracted from bovine pineal glands5

  • expert opinionEpitalon has been extensively studied using in vitro, in vivo, and in silico methods over the last 25 years6

  • expert opinionEpithalamin is a crude polypeptide extract of bovine pineal glands while epithalon is a tetrapeptide isolate (Ala-Glu-Asp-Gly) from epithalamin that can also be made synthetically17

  • expert opinionThere is no evidence to suggest that either epithalamin or epithalon affects APOE4 carriers differently than non-carriers17

  • expert opinionEpithalon was designed in Russia as a short, stable analog of Epithalamin, a polypeptide extract of the pineal gland21

Show the remaining 6

  • expert opinionMuch of the work is decades old, has not been widely replicated by independent groups outside Russia, and the modern human data are limited in size and rigor21

  • expert opinionEpitalon originated at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson beginning in the 1980s23

  • expert opinionEpithalon (Ala-Glu-Asp-Gly) is a tetrapeptide developed at the St. Petersburg Institute of Bioregulation and Gerontology28

  • theoreticalEpithalon is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG) and a molecular weight of 390.35 g/mol5

  • theoreticalAEDG peptide was first detected as a natural component of the pineal gland in 20175

  • theoreticalEpitalon is a naturally occurring tetrapeptide7

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

There are no human RCTs or hard-endpoint trials showing epithalon extends human lifespan.

Multiple sources state no large-scale randomized controlled trials exist in humans, no Phase 2/3 hard-endpoint trials have been published, and there is no human trial showing epithalon extends human life. Human data is limited to small, decades-old observational cohorts with variable blinding.

Single source

Most human and telomerase research comes from a single Russian research group.

Sources note that much of the published research (including the mortality datasets and telomerase findings) originates from Khavinson's St. Petersburg group over roughly four decades, and independent replication of the human clinical findings has been limited or absent. One source noted 266-patient mortality data came from 'one Russian lab.'

Contested

Replication of the telomerase/telomere effect is partial and its human relevance is unconfirmed.

The 2003 telomerase finding was reportedly replicated in vitro in 2025 (Epithalon: 266 Patients, FDA PCAC Review Jul 2026 | Kalios, Epithalon: Research Evidence & Safety Profile | PeptideInsight, Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.), but other sources caution the telomerase reactivation has not been independently replicated in Western labs 'at the same magnitude' (Epitalon: 2026 Dosing & Telomere Evidence Review), that epigenetic binding-affinity data has not been broadly replicated (Epitalon: 2026 Dosing & Telomere Evidence Review), and that telomere effects are not confirmed in human clinical settings (Epithalon and Telomere Research: What Science Knows So Far - Peptides FYI).

Contested

Reported dosing varies enormously across sources, from sub-milligram to 10 mg daily.

Dosing recommendations range widely: 0.5-1.0 mg daily (Epitalon Peptide: Mechanism, Dosing & Safety | pin.board), 5 mg or 10 mg daily (Epithalon: The Telomere Peptide From Russia | PepAtlas), 5-10 mg daily (Epithalon Dosing, Need to Know Information, Safety,… | Peptide Initiative), and 10 mg IM daily in Russian/Ukrainian clinical protocols (Epithalon Monograph Final.pages). Course length (10-20 days), frequency (1-3x/year), and route also vary, and one review explicitly flags optimal dosing regimens as a knowledge gap.

Contested

Sources disagree on epithalon's plasma half-life and mechanism specifics.

Most sources report a plasma half-life of about 30 minutes with degradation within minutes (Epithalon: 266 Patients, FDA PCAC Review Jul 2026 | Kalios, Epitalon: 2026 Dosing & Telomere Evidence Review, Epithalon: The Telomere Peptide From Russia | PepAtlas, How Long Epithalon Stays in System — Half-Life and), while one source estimates 2-4 hours (Epithalon Dosing, Need to Know Information, Safety,… | Peptide Initiative). There is also a species discrepancy on melatonin: epithalon reportedly failed to stimulate melatonin in rats but increased it in primates (Epithalamin/Epithalon).

Limited evidence

Much of the underlying literature is old, in Russian, and preclinical/mechanistic.

Roughly half of the ~110 published articles are in Russian (Epithalamin/Epithalon); a large share of substantive evidence is in vitro or animal (telomerase, lifespan, tumor, oocyte, gene-expression studies), and reviews note preclinical promise but a lack of clinical trials and systematic validation.

What you may have heard

The claims that make Epithalon famous — switching on telomerase, extending lifespan, and lowering mortality — are not backed by strong human evidence.

The only human study rated in the strongest evidence category looks narrowly at leukocyte circadian-gene expression and urinary melatonin markers (published in a Russian gerontology journal). It does not establish the peptide's marquee anti-aging claims. Telomerase activation and telomere lengthening come from cell-culture experiments (the 2003 Khavinson work and a 2025 replication in cell lines); lifespan extension comes from flies, mice, and rats; and the reduced-mortality figures come from small, unreplicated Russian cohorts, often combined with another peptide, thymalin. A lone strong observational study on circadian genes does not make the whole body of evidence robust.

Other

The 2025 finding that epithalon extends telomeres in telomerase-positive cancer cell lines is presented neutrally and no…

Overview reports epithalon extended telomeres in cancer lines (via ALT per Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.). Telomere elongation in malignant cells is a direct pro-survival/pro-proliferation signal, yet the safety section frames the oncology issue only as a 'theoretical' telomerase concern and reassures with animal tumor-reduction data. The in vitro cancer-cell telomere extension is a concrete, source-backed red flag the safety section omits.

What you may have heard

The claim that this peptide extends telomeres through a recombination-based mechanism in cancer cells rests on a single in vitro study.

One cell-line study, 'Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity', reports that in normal epithelial and fibroblast cells epitalon extended telomeres in a dose-dependent way through hTERT and telomerase upregulation, while in the breast cancer lines tested (21NT, BT474) telomere extension instead occurred through Alternative Lengthening of Telomeres (ALT) activation, with only minor ALT activity in normal cells. This normal-versus-cancer split in mechanism comes from that single study, and no independent replication is available to confirm the cell-type-specific switch.

What you may have heard

Histone binding energies of -56.49 and -64.51 kcal/mol are implausibly large for docking/binding scores.

Typical peptide/small-molecule docking or binding free energies fall roughly in the -5 to -20 kcal/mol range; values near -60 kcal/mol suggest a different computational method (e.g., MM/GBSA interaction energy) or a units/reporting error. Presenting these as binding energies without qualification may misrepresent the in silico result.

What you may have heard

'Functional effects last weeks to months' and 'nighttime melatonin persists for several days after a single dose' overst…

With a ~30 min plasma half-life, claims of effects lasting weeks-to-months (attributed claim 43) rest on in vitro hTERT mRNA timing and anecdotal melatonin persistence, not human PK/PD data. This disconnect is then used to justify pulsed dosing. The certainty of durable multi-week effects exceeds what the cited (largely tier-3/anecdotal) sources support.

What you may have heard

Antioxidant potency '~1000-fold more potent than epithalamin' and 'comparable to melatonin' is a questionable, strong co…

Epithalamin is a crude polypeptide extract, so a molar/concentration potency comparison against a pure tetrapeptide is not directly meaningful (1000-fold 'lower concentration' vs an undefined mixture). The 'comparable to melatonin' antioxidant claim is presented with more certainty than two sources (one tier 2, one tier 3) warrant.

Inconsistency

'Effective clearance within 24-48 hours' sits awkwardly with a 30-min half-life and 87.5% degradation in 90 minutes.

If ~87.5% is degraded within 90 minutes (≈3 half-lives), the compound is essentially gone within a few hours, not 24-48 hours. The two figures describe very different clearance timescales and should be reconciled or clarified (parent peptide vs fragments).

Inconsistency

Peptide described both as synthetic (developed in 1980s from epithalamin) and 'naturally occurring / first detected in t…

These framings coexist without reconciliation; the '2017 natural detection' claim leans on Epithalon: Research Evidence & Safety Profile | PeptideInsight/Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. and should be checked, since it materially affects whether epithalon is characterized as endogenous or a wholly synthetic construct.

What you may have heard

266-patient mortality data (1.6-4.1x fewer deaths) presented from a single tier-3 marketing source with a future-dated t…

Epithalon: 266 Patients, FDA PCAC Review Jul 2026 | Kalios's title references an 'FDA PCAC Review Jul 2026' (a future date) and is a tier-3 commercial source; the striking mortality reduction figure is single-sourced and often confounded by co-administered thymalin. The caveat notes single-group origin but the specific magnitude deserves reviewer scrutiny for provenance.

Contested

The melatonin surge and the restored day-night rhythm are reported in two separate review articles about the same pineal tetrapeptide, not shown together in one documented study.

Both effects are described for the tetrapeptide Ala-Glu-Asp-Gly in old rhesus monkeys, but they come from different review-level sources and under slightly different names. '[Aging of the pineal gland]' reports that this peptide (there written Epithalon) produced a threefold increase in nocturnal melatonin peaks in old rhesus monkeys. 'Peptides and Ageing' reports that the same tetrapeptide (there written Epitalon) restored the circadian rhythms of melatonin and cortisol production in old rhesus monkeys. Both are summary reviews; neither source, as presented, details the underlying primary experiments or establishes that the two effects were observed in the same animals.

What you may have heard

The only top-tier human study of epithalon is a single small trial on circadian-gene activity; its headline telomerase and lifespan claims rest on lab-dish and animal experiments.

Epithalon is often presented as strongly evidenced, but the single strongest human study is a small observational trial showing it raised a melatonin breakdown product (6-sulfatoxymelatonin) about 1.7-fold and normalized circadian clock-gene expression (Clock, Csnk1e, Cry2) in people with reduced pineal function. The reasons most people are interested in epithalon — that it switches on telomerase, lengthens telomeres, extends lifespan, and lowers mortality — come from cell-culture experiments and rodent studies, largely from a single Russian research group, plus small unreplicated human cohorts. No human trial has confirmed the telomere or longevity claims.

Using it with other compounds

Check a stack
  • MOTS-cComplementary

    No documented conflict

    Both are longevity-oriented peptides converging on antioxidant defense and metabolic/mitochondrial health via distinct mechanisms — MOTS-c drives AMPK/PGC-1α mitochondrial biogenesis and NRF2 antioxidant response, while Epithalon works through telomerase, senescence-pathway, and circadian/antioxidant modulation. Complementary geroprotective strategies.

    Tier 4Theoretical — not established
  • GHK-CuComplementary

    No documented conflict

    Both have broad anti-aging profiles targeting antioxidant defense and cellular senescence, but via separate pathways — GHK-Cu acts through SIRT1/Nrf2/FoxO3a gene modulation and tissue repair, while Epithalon works through telomerase activation and p16/p21 senescence pathways. Complementary approaches to reducing senescence burden.

    Tier 4Theoretical — not established
  • SemaxComplementary

    No documented conflict

    Semax drives BDNF/NGF neurotrophin signaling for cognitive and neuroprotective effects, a mechanism distinct from Epithalon's antioxidant/senescence and circadian actions. The two hit neurogenesis and brain protection through separate pathways and may be complementary.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms explicitly support neurogenesis as a shared dimension through distinct pathways: Epithalon lists 'neurogenesis' as an approved tag and describes 'neuroprotective and neurogenic effects' via antioxidant/senescence pathways and circadian regulation; Semax lists 'neurogenesis' as an approved tag and achieves neuroprotection through BDNF/NGF-TrkB neurotrophin signaling. The proposed relationship correctly identifies that they target neurogenesis through mechanistically separate pathways (Epithalon via telomerase/senescence/circadian mechanisms; Semax via BDNF/TrkB signaling), making them complementary rather than redundant. This aligns with the mechanism descriptions provided.

    Shares neurogenesis

  • SS-31Complementary

    No documented conflict

    SS-31 stabilizes cardiolipin and cuts mitochondrial ROS at the source, whereas Epithalon's reported benefits run through telomerase and general antioxidant/senescence pathways. Both reduce oxidative/mitochondrial aging burden via unrelated mechanisms, making them plausibly complementary.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms establish mitochondrial_function as a shared dimension through distinct pathways: SS-31 directly targets cardiolipin, mPTP, and ETC supercomplexes to reduce mitochondrial ROS production and preserve mitochondrial structure; Epithalon activates telomerase and antioxidant pathways while modulating mitochondrial ROS. The proposed relationship as 'complementary' is justified—they address mitochondrial aging burden through unrelated mechanisms (direct mitochondrial targeting vs. telomerase/antioxidant upregulation), making them mechanistically non-overlapping yet synergistic for the shared dimension of mitochondrial function. Both peptides' approved tags include 'mitochondrial_function,' confirming this shared dimension is recognized in their mechanism profiles.

    Shares mitochondrial function

  • HumaninComplementary

    No documented conflict

    Both are studied as geroprotective peptides that reduce oxidative stress and are reported to extend healthspan in animal models, but epithalon acts on telomerase/hTERT and circadian-melatonin gene regulation while humanin works through mitochondrial cytoprotection. Distinct anti-aging mechanisms with a shared longevity goal.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms support a complementary relationship focused on mitochondrial_function and geroprotection. Humanin is explicitly described as a 'mitokine' encoded in the mitochondrial genome that enhances mitochondrial biogenesis/bioenergetics and has approved tag 'mitochondrial_function.' Epithalon has the same approved tag 'mitochondrial_function' and includes antioxidant/mitochondrial ROS modulation in its pathways. Both are reported to extend lifespan/healthspan in animal models through distinct mechanisms—humanin via direct mitochondrial cytoprotection and anti-apoptosis, epithalon via telomerase activation and circadian-melatonin restoration. The explanation accurately characterizes these as complementary (non-overlapping but synergistic) approaches to geroprotection that both address mitochondrial function and oxidative stress, justifying the proposed relationship and shared dimension.

    Shares mitochondrial function

  • PinealonSame mechanism

    Worth caution

    Both are short Khavinson-school 'peptide bioregulators' proposed to act by binding DNA/histones and switching gene expression rather than a membrane receptor, and both are pitched as neuroprotective/neurogenic with effects on circadian and melatonin biology. Because they share the same class and proposed mechanism, running them together is largely redundant rather than additive — pick one for your goal rather than stacking two overlapping bioregulators.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    While both peptides are synthetic short peptides proposed to interact with DNA/histones, the mechanism material does not establish they share the same mechanism. Epithalon's mechanisms are explicitly centered on telomerase/hTERT upregulation, telomere elongation, and senescence pathway modulation (p16/p21), with circadian/melatonin effects as secondary outcomes. Pinealon's mechanisms focus on MAPK/ERK signaling, caspase-3/p53 apoptotic pathways, and antioxidant enzyme expression (SOD2, GPX1), with circadian/melatonin effects only 'proposed' and 'theoretical.' The DNA/histone binding is proposed for both, but the downstream pathways and primary therapeutic targets differ substantially. Neurogenesis is tagged for Pinealon only; Epithalon's neurogenic effects are mentioned but not mechanistically detailed in the same way. The claim of redundancy due to 'same class and proposed mechanism' overgeneralizes from shared structural features (short peptides, DNA-binding hypothesis) without demonstrating convergent pathway activation. The mechanisms do not support that these peptides operate via the same molecular logic.

    Shares neurogenesis

  • DSIPSame downstream effect

    May be complementary

    Both peptides converge on restoring normal melatonin secretion and circadian rhythm, but by different upstream mechanisms: DSIP influences pineal melatonin synthesis and delta sleep, while Epithalon reportedly upregulates the pineal melatonin (AANAT) axis and circadian clock genes. Used together they could reinforce circadian normalization and sleep timing.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms explicitly converge on the melatonin pathway and circadian rhythm restoration via distinct upstream mechanisms. DSIP's mechanism includes 'Circadian/melatonin (pineal NAT, melatonin, serotonin, 5-methoxytryptophol)' and effects on sleep architecture. Epithalon's mechanism explicitly includes 'Melatonin biosynthesis (AANAT / pineal axis)' and 'Circadian gene regulation (Clock, Csnk1e, Cry2)' with restoration of melatonin secretion and circadian rhythms as documented effects. Both are tagged with 'melatonin_pathway'. The proposed relationship correctly identifies that they target the same downstream outcome (melatonin/circadian restoration) through different upstream pathways (DSIP via GABAergic/sleep-promoting mechanisms; Epithalon via telomerase/epigenetic mechanisms), which is precisely what 'same_downstream' describes.

    Timing Take in the evening to reinforce the natural nighttime melatonin rise and consolidate circadian effects.

    Shares melatonin pathway

  • CerebrolysinComplementary

    No documented conflict

    Epithalon contributes antioxidant, geroprotective and neurogenic effects with mitochondrial ROS modulation, complementing Cerebrolysin's neurotrophic and energy-metabolism support. Different mechanisms converging on neuronal health; combination evidence is anecdotal.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly support the claimed shared dimensions. For mitochondrial_function: Cerebrolysin explicitly includes 'mitochondrial_function' tag and 'Improved neuronal energy metabolism' effect; Epithalon includes 'mitochondrial_function' tag and 'Antioxidant / mitochondrial ROS modulation' pathway. For neurogenesis: both peptides explicitly list 'neurogenesis' in their approved tags and describe neurogenic effects (Cerebrolysin: 'neurogenesis and synaptogenesis'; Epithalon: 'Neuroprotective and neurogenic effects'). The explanation accurately characterizes their mechanisms as complementary—Epithalon targets cellular senescence and oxidative stress at the mitochondrial level while Cerebrolysin provides neurotrophic support and metabolic enhancement—representing different but convergent approaches to neuronal health. The mechanisms do not contradict this relationship; they support it.

    Shares mitochondrial function · neurogenesis

Safety and side effects

Safety and Tolerability

Epithalon and its parent extract epithalamin are generally described as well tolerated with a favorable safety profile, with no consistent pattern of serious toxicity at the doses studied. Two 3-year epithalamin treatment trials (one with 12-year follow-up) reported no severe adverse events in older adults, and limited evidence suggests epithalamin is likely safe for long-term use.

Reported Adverse Effects

Reported adverse effects and user experiences are typically mild and self-limiting, and are consistent with pineal/circadian axis activation:

  • Vivid dreams (reported almost universally)
  • Deep sleep during the first few nights
  • Mild next-day drowsiness at higher doses
  • Minor, brief injection-site tenderness

Theoretical and Unresolved Concerns

  • Telomerase and oncology: There is a theoretical oncological concern about inducing telomerase activity in adult somatic cells — a phenomenon rare outside stem-cell and germline contexts. This concern has not been adequately addressed. Notably, animal data point in the opposite direction (reduced spontaneous and induced tumor incidence), but the theoretical risk in humans remains unresolved.
  • Lack of long-term human safety data: As a non-approved peptide, epithalon lacks long-term safety data and systematic validation.
  • Limited, single-group human data: Human safety observations come largely from small cohorts, many from a single Russian research group, without independent confirmation.

Regulatory Note

Epithalon is unscheduled and not approved for any indication in the US, has had no FDA or EMA review, carries an FDA Category 2 designation (Oct 2023), and is banned from compounding. It should be regarded as a research compound.

  • Telomere extension observed in cancer cells: Beyond the general theoretical concern, a 2025 in vitro study (Siddiqui/Al-Dulaimi et al., PMID 40908429) reported that epithalon extended telomeres in telomerase-positive breast cancer cell lines, primarily via the Alternative Lengthening of Telomeres (ALT) pathway. Telomere elongation in malignant cells is a pro-survival/pro-proliferation signal, so this is a concrete laboratory observation rather than a purely hypothetical risk. Its clinical significance in humans is unknown and has not been studied, but anyone with a personal or strong family history of cancer should weigh it and consult a clinician before use.

Reconstitution and handling

Reconstitution

No dose has been established for this compound. No regulatory label exists for it, so the figures below are what sources report — not guidance.

Epithalon is supplied as a lyophilized (freeze-dried) powder and must be reconstituted before use. A commonly described preparation:

  • A 10 mg vial reconstituted with 2 mL bacteriostatic water yields a concentration of 5 mg/mL.
  • At that concentration, a 5 mg dose corresponds to 100 units (1.0 mL) on a U-100 insulin syringe.

Bacteriostatic water is directed slowly against the vial wall; the powder is allowed to dissolve without vigorous shaking. Reconstituted solution is typically refrigerated.

Route of Administration

Epithalon is orally inactive. The standard research route is subcutaneous injection. Some studies of the parent pineal preparation used intramuscular or intranasal routes.

Reported Dosing Protocols (research/community)

Reported dosing varies enormously across sources — from sub-milligram to 10 mg daily — and optimal regimens are explicitly flagged as a knowledge gap. Reported ranges include:

  • Common community/protocol dosing: 10-20 day courses repeated 1-2 (or 1-3) times per year. A frequently cited protocol is 5 mg SC daily for 20 consecutive days, or 10 mg daily for 10 days, with 4-6 month off periods.
  • Lower-dose reports: 0.5-1.0 mg daily SC for 10-20 days, twice per year; or 5-10 mg daily for 10-20 day courses, with courses repeated monthly or quarterly.
  • Russian/Ukrainian intramuscular protocols: 100 mg total (10 mg IM daily for 10 days, twice a year), or 50 mg total (10 mg every third day over 2 weeks, twice a year).

Pharmacokinetic Context

Despite a short plasma half-life (~30 minutes per most sources; up to 2-4 hours per one source), reported functional effects persist much longer — telomerase (hTERT mRNA) activation peaks 24-36 hours post-injection in vitro, and elevated nighttime melatonin reportedly persists for several days after a single dose. This apparent disconnect between rapid clearance and prolonged downstream effects is often cited as a rationale for intermittent, pulsed course-based dosing rather than continuous administration.

Important Note

These figures are reported research and community protocols, not medical guidance. Epithalon is a non-approved research compound with no established human dosing standard, and reported protocols conflict widely.

Sources

Ordered by evidence quality — the strongest first.

  1. [AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging.].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  2. Epithalon Peptide Induces Telomerase Activity and ...(opens in a new tab)
    Tier 2Web · researchgate.net
  3. Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  4. Epithalon and Telomere Research: What Science Knows So Far - Peptides FYI(opens in a new tab)
    Tier 2Web · peptides.fyi · 2026
  5. Epithalon: Research Evidence & Safety Profile | PeptideInsight(opens in a new tab)
    Tier 2Web · peptideinsight.com · 2026
  6. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide ...(opens in a new tab)
    Tier 2Web · pubmed.ncbi.nlm.nih.gov · 2025
  7. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  8. The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  9. Epitalon protects against post-ovulatory aging-related damage of mouse oocytes.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  10. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  11. Short Peptides Protect Oral Stem Cells from Ageing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  12. [Aging of the pineal gland].(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  13. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  14. Peptides and Ageing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  15. Studies of the effects of Vilon and Epithalon on gene expression in mouse heart using DNA-microarray technology.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  16. Epitalon Peptide: Mechanism, Dosing & Safety | pin.board(opens in a new tab)
    Tier 3Web · blog.pinned.life
  17. Epithalamin/Epithalon(opens in a new tab)
    Tier 3Web · alzdiscovery.org
  18. Epithalon | Reviews, Clinical Trials, and Safety(opens in a new tab)
    Tier 3Web · peptides.org
  19. Epithalon Dosing, Need to Know Information, Safety,… | Peptide Initiative(opens in a new tab)
    Tier 3Web · peptideinitiative.com
  20. Epithalon Monograph Final.pages(opens in a new tab)
    Tier 3Web · peptidesociety.org
  21. Epithalon Peptide: Uses, Evidence & Safety | Strong Health(opens in a new tab)
    Tier 3Web · stronghealth.com
  22. How Long Epithalon Stays in System — Half-Life and(opens in a new tab)
    Tier 3Web · realpeptides.co
  23. Epitalon: 2026 Dosing & Telomere Evidence Review(opens in a new tab)
    Tier 3Web · thepeptidetoolkit.com · 2026
  24. Epithalon: 266 Patients, FDA PCAC Review Jul 2026 | Kalios(opens in a new tab)
    Tier 3Web · kalios.health · 2026
  25. Epithalon: The Telomere Peptide From Russia | PepAtlas(opens in a new tab)
    Tier 3Web · pepatlas.com · 2026
  26. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  27. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2026
  28. Epithalon and Telomere Biology: Current Evidence and Future Directions(opens in a new tab)
    Tier 3Web · thepeptidedispatch.com · 2024
  29. Peptide Regulation of Cell Differentiation.(opens in a new tab)
    Tier 4PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  30. An Efficient Data-Gathering Routing Protocol for Underwater Wireless Sensor Networks.(opens in a new tab)
    Tier 4PubMed · pubmed.ncbi.nlm.nih.gov · 2015